HENGRUI PHARMA (01276) announced that the company recently received the "Drug Clinical Trial Approval Notice" for HRS-2430 injection issued by the National Medical Products Administration (NMPA). Clinical trials will commence in the near future.
HRS-2430 injection is an intravenous general anesthetic. Marketed drugs in the same category include etomidate, midazolam, and remimazolam. According to research, the combined global sales of etomidate, midazolam, and remimazolam in 2024 amounted to approximately $773 million. As of now, the cumulative R&D investment in the HRS-2430 injection project has reached around 24.6 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.